Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Upcoming milestones

Upcoming milestones

The following list, while not definitive, represents a significant portion of later-stage milestones anticipated by biotechnology companies over the next six to nine months. The criteria for selection were probable completion of Phase II studies or later milestones, including regulatory approvals. If some company milestones have been overlooked, please fax the pertinent information to 415/595-5589 for use in a supplemental table in a future edition of BioCentury.

Read the full 688 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers